We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Artificial Intelligence Accurately Predicts Breast Cancer Years Before Diagnosis

By HospiMedica International staff writers
Posted on 16 Oct 2024

Mammography screening helps reduce breast cancer mortality; however, its accuracy is not perfect. More...

For decades, various strategies have been employed to enhance the interpretive performance of mammography, including double reading. Recently, several commercial artificial intelligence (AI) algorithms have received regulatory approval as supplementary tools for radiologists, showing promising results in detecting cancer on mammograms. These AI algorithms are designed to highlight areas of concern and provide breast-level and examination-level malignant neoplasm scores to assist interpreting radiologists. However, emerging research indicates that these same AI scores may also identify imaging features linked to future breast cancer years before they are clinically diagnosed. If commercial AI algorithms developed for immediate cancer detection can also assess future cancer risk, then more accurate and reliable short-term risk estimation could facilitate personalized preventive measures (e.g., more frequent or supplemental imaging), potentially leading to earlier breast cancer detection and less aggressive treatment. Analyses of AI breast cancer detection scores from consecutive mammography screenings prior to diagnoses are essential to evaluate the potential of these tools for estimating future disease risk. A new study has now investigated whether a commercial AI algorithm for breast cancer detection could predict the development of future cancer.

This collaborative study involving researchers from the Norwegian Institute of Public Health (NIPH, Oslo, Norway) utilized AI cancer detection scores recorded during multiple consecutive screening rounds of the national screening program, BreastScreen Norway. The researchers combined consecutive AI scores with long-term cancer outcomes to determine whether Lunit Inc.’s (Seoul, South Korea) INSIGHT MMG, a regulatory-cleared commercial AI algorithm for breast cancer detection, could estimate the onset of future breast cancers identified in subsequent screening rounds. Lunit INSIGHT MMG analyzes mammography images with 97% accuracy, pinpointing lesions that are suspicious for breast cancer and providing an abnormality score reflecting the likelihood of the existence of detected lesions.

This retrospective cohort study included 116,495 women aged 50 to 69 years who had no prior history of breast cancer and underwent at least three consecutive biennial screening examinations. The researchers employed scores from INSIGHT MMG for breast cancer detection and gathered screening data from multiple consecutive rounds of mammography. The study findings, published in JAMA, indicate that INSIGHT MMG could signal breast cancer up to six years before it develops. The AI system’s discriminatory accuracy for predicting future screening-detected or interval cancer risk 4 to 6 years before diagnosis met or exceeded the performance of established risk calculators currently in widespread use. These results suggest that commercial AI algorithms could help identify women at high risk of developing future breast cancer, paving the way for personalized screening strategies to facilitate earlier diagnosis.

Related Links:
NIPH
Lunit Inc.


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Surgical System
Stealth AXiS
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Illustration of the Hēlo Thrombectomy System device (Photo courtesty of Endovascular Engineering)

FDA-Cleared Thrombectomy System Removes Pulmonary Embolism Clots

Pulmonary embolism occurs when blood clots travel to the lungs and block blood flow, potentially requiring urgent endovascular intervention to prevent death. Catheter-based clot removal can be challenging,... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.